A study to investigate the palliative benefit of Complex supplements for seasonal allergic conjunctivitis

A study to investigate the palliative benefit of Complex supplements for seasonal allergic conjunctivitis - A study to investigate the palliative benefit of Complex supplements for seasonal allergic conjunctivitis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000030863

Enrollment

Registered

2018-01-31

Start date

2018-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Seasonal allergic conjunctivitis

Interventions

Ingestion of Complex supplements (Dosage (1)) component food (8 weeks) Ingestion of Complex supplements (Dosage (2)) component food (8 weeks) Ingestion of Complex supplements not containing component

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Subjects who is adults of both sexes above 20 years old 2) Subjects who competent to consent and give voluntary consent in writing with full understanding after reading briefing paper of this study aim and contents 3) Subjects with cedar pollen allergy 4) Subjects without any disease, lesion or malfunction on anterior segment of the eye

Exclusion criteria

Exclusion criteria: 1) Subjects with systemic illness that effects on health of the eye 2) Subjects who are in pregnancy, or lactation 3) Subjects who are receiving medical treatment except Artificial tears on local or entire body that affects the study 4) Subjects with Infectious eye disease 5) Subjects who have Systemic activity allergic disease (Asthma, Hives, Anaphylaxis etc) 6) Subjects with allergy to the food to be examined 7) Subjects who participate in other clinical trial currently, or participated in other clinical trial within 1 month prior to obtaining informed consent 8) Subjects who are under initial therapy for allergy to pollen 9) Subjects who are under treatment with medicinal product that is not anti-allergic medicine for this study, or subjects who are planning to use those medical drugs 10) Any candidates considered to be unsuitable for enrollment in the opinion of physician-in-charge

Design outcomes

Primary

Measure	Time frame
QOL related questionnaire scores	—

Secondary

Measure	Time frame
Combination drug(anti-allergic medicine)The number of times of usage - time of initiation of usage QOL related questionnaire scores(interfere with everyday activities,condition)	—

Countries

Japan

Contacts

Public ContactShigeru Imai

CROee.INC Evidence Division

imai@croee.com03-5953-2108

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026